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Abstracts / Biol Blood Marrow Transplant 20 (2014) S211eS256S232allogeneic hematopoietic stem cell transplantation. In an
effort to balance the risks of transplant-related mortality
(TRM) associated with high-dose myeloablative (MA) con-
ditioning against the risk of relapse after non-myeloablative
(NMA) conditioning in cord blood transplantation (CBT), we
investigated CBT using a novel RIC regimen of cyclophos-
phamide 50mg/kg, ﬂudarabine 150mg/m2, thiotepa 10mg/kg
and 400 cGy total body irradiation (Cy50/Flu150/Thio10/
TBI400), with favorable results (Ponce et al, BBMT 2013). We
now report outcomes of allograft using this conditioning
regimen and adult donors.
Methods: Twenty consecutive patients (median age 51 years,
range 27-69) underwent Cy50/Flu150/Thio10/TBI400 condi-
tioning for the treatment of AML (CR1 ¼ 2, CRi ¼ 2, relapse ¼
2), ALL (CR2¼1, PR¼1) CMML (CR ¼ 1, PR ¼ 1), NHL (CR1 ¼ 2,
CR2 ¼ 1, CR3 ¼ 1, refractory ¼ 5) and plasmacytoid dendritic
neoplasm (n ¼ 1). Most (n ¼ 16) had high-risk disease and a
median HCT-CI of 1 (range 0-7). All patients received
unmodiﬁed peripheral blood stem cell transplants (9 HLA-
matched related, 9 HLA-matched unrelated, and 2 HLA-
mismatched unrelated donors). Graft-versus-host disease
(GVHD) prophylaxis was with tacrolimus/methotrexate
(MTX) (n ¼ 5), ortacrolimus/sirolimus with MTX (n ¼ 12) or
without MTX (n ¼ 3). One recipient of a mismatched graft
also received anti-thymocyte globulin.
Results: All patients engrafted with a median time to
neutrophil engraftment of 12 days (range 9-19). The cumu-
lative incidence of day 100 grade II acute GVHDwas 30% (95%
CI: 12-51) with no patient having grade III-IV disease. At 2
years, 42% (95%CI: 19-64) of patients had developed chronic
GVHD of whom 2 patients had moderate and 2 had severe
disease. Two-year TRM was 23% (95%CI: 6-46) with 2 pa-
tients dying of GVHD and 2 from organ toxicity. With a
median follow-up of survivors of 19.4months (range 4.1-59.1
months), the 1 and 2-year overall survival (OS) are 74% (95%
CI: 48-88) and 59% (95%CI: 32-79), and 1 and 2-year pro-
gression-free survival (PFS) are 68% (95%CI: 43-85) and 53%
(95%CI: 27-74), respectively.
Conclusion: Adult donor allograft after Cy50/Flu150/Thio10/
TBI400 conditioning is associated with high rates of
engraftment, acceptable TRM, and promising OS and PFS in
patients with high-risk hematologic malignancies. This
regimen is an alternative to both high-dose MA and NMA
conditioning and warrants further prospective investigation.Figure 1.358
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) utilizing myeloablative conditioning is
associated with high treatment-related mortality (TRM). In
an effort to reduce TRM yet maintain myeloablative efﬁcacy
we employed Fludarabine, intravenous Busulfan and total
body irradiation 400 cGy (Flu/Bu/TBI). We present our single
institution experience with this regimen.
Method: We conducted a retrospective analysis of 89 pa-
tients who underwent Flu/BU/TBI conditioning regimen
prior to allogeneic HSCT at our institution between the years
2007 and 2012. Flu/Bu/TBI consisted of intravenous(IV)
Fludarabine 50 mg/m2 infused over 30 minutes for 5 days
on days -6 through day -2 and IV Busulfan 3.2 mg/kg/day on
days -5 and e2 (infusion rate 80 mg/kg/hr) and TBI of
400cGY administered in divided doses on day -1 and 0. All
patients received Thymoglobulin at a dose of 4.5mg/kg or 6
mg/kg administered in divided doses on days -2, -1, and 0.
Post transplantation graft versus host disease (GVHD) pro-
phylaxis consisted of tacrolimus and mycophenolate mofe-
til. Diagnoses included Acute Myeloid Leukemia (AML)
(n¼37), Acute Lymphoblastic Leukemia (ALL) (n¼19), Mye-
lodysplastic Syndrome (MDS) (n¼10), Non-Hodgkins Lym-
phoma (NHL) (n¼12), and others (n¼11). The median age of
entire cohort was 50 years (range 21-68). CIBMTR risk
stratiﬁcation of the patients revealed high risk in the ma-
jority with only 30 (34%) patients achieving CR1 or CR2
status prior to transplant. Fourty-ﬁve (51%) patients had a
comorbidity score of 2.
Results: 1 and 3 year overall survival (OS) for the entire
cohort was 46.9% and 34.6%. OS in patients in CR when
compared to those not in CR, was signiﬁcantly better at 1 and
3 years at 73% and 55% compared to 34% and 24%( p<0.001).
OS in patients who achieved CR and had low CMS was 78% at
1 year. Cumulative incidence of progression and relapse free
survival for the entire cohort was 60.7% and 55.5% at 1 and 3
years. In patients who achieved CR, relapse free survival was
signiﬁcant at 81% and 68% at 1 and 3 years (p<0.039). Inci-
dence of grade 2 acute GVHD was 19% and grades 3-4
was12.3%. Cumulative incidence of treatment related mor-
tality (TRM) for the entire cohort at 3 years was 30.4%, but for
patients who achieved CR, the TRMwas signiﬁcantly lower at
13.3% (p<0.05)
Conclusion: Our data shows that FluBuTBI conditioning is
a well-tolerated conditioning regimen, which can provide
adequate cytoreduction while maintaining acceptable
TRM. The results are particularly encouraging for patients
who achieve remission prior to transplant and those with
low comorbidity score. In agreement with previous pub-
lications, our ﬁndings suggest that FluBuTBI is a reason-
able alternative to the traditionally used myeloablative
regimens.
